Palisade Bio, Inc. (PALI)

NASDAQ: PALI · Real-Time Price · USD

1.800

0.00 (0.00%)

Dec 5, 2025, 4:00 PM EST - Market closed

Palisade Bio Employees

Palisade Bio had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.

Employees

8

Change (1Y)

-1

Growth (1Y)

-11.11%

Revenue / Employee

n/a

Profits / Employee

-$1,403,250

Market Cap

268.21M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	8	-1	-11.11%
Dec 31, 2023	9	-3	-25.00%
Dec 31, 2022	12	-1	-7.69%
Dec 31, 2021	13	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

PALI News

3 days ago - Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development - GlobeNewsWire
10 days ago - Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
5 weeks ago - Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations - GlobeNewsWire
6 weeks ago - Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD) - GlobeNewsWire
7 weeks ago - Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewsWire
2 months ago - Palisade Bio Announces Cancellation of Special Meeting of Stockholders - GlobeNewsWire
2 months ago - Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option - GlobeNewsWire
2 months ago - Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - GlobeNewsWire